Biotech RadarJobs updated

COMPANY

Convergent Therapeutics

HQ: Cambridge, MA source · convergentrx.com ↗

Clinical Phase 2

Keywords: oncology cancer PSMA PET-Positive Castration-Resistant Prostate Cancer

Location: Cambridge, MA · source · Aug 13, 2024

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Ca source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

RecordTitlePhaseStatusStartPrimary completion
NCT06549465Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)Phase 2RecruitingAug 6, 20242027-08 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback